tti-621

Recombinant proteinexperimental

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • tti-621

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05507541Phase 2Jan 15, 2023Mayo Clinic, National Cancer Institute (NCI)
NCT05139225Phase 1Oct 28, 2021Memorial Sloan-Kettering Cancer Center, Trillium Therapeutics Inc.
NCT04996004Phase 1/Phase 2 (Phase 2)Jun 25, 2021Trillium Therapeutics Inc.
NCT02890368Phase 1Sep 1, 2016Trillium Therapeutics Inc.
NCT02663518Phase 1Jan 1, 2016Trillium Therapeutics Inc.
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Trillium Therapeutics Inc.For profit4322016
Mayo ClinicAcademic/Hospital1112023
Memorial Sloan-Kettering Cancer CenterAcademic/Hospital1112021
National Cancer Institute (NCI)Government1012023
4 organizations
Page 1 / 1